With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
The response rates to imatinib among certain populations of patients with GIST. That’s why a novel oral drug avapritinib is now approved specifically for GIST with PDGFRA exon 18 mutations after a phase 1 trial reported a response rate approaching 90%. | FDA 2020